Five neutralizing monoclonal antibodies produced against human rotavirus (HRV) serotypes 1, 2, 3 and 4 and the simian rotavirus (SA1 l) were used to study 59 rotavirus isolates of human, simian and feline origin previously serotyped using polyclonal antisera. In neutralization tests, 19 of 26 HRV serotype 1 isolates, both strains of HRV serotype 2, 14 of 24 HRV serotype 3 isolates and all of seven serotype 4 isolates were neutralized by the homologous serotype-specific monoclonal antibodies. Use of the panel of monoclonal antibodies revealed antigenic differences between strains within serotypes 1 and 3 and, in the case of the serotype 3 strains, each variant had a unique RNA electropherotype. An enzyme immunoassay (EIA) which utilized the monoclonal antibodies essentially confirmed the neutralization results. Preliminary results show that direct serotyping in faecal extracts by EIA using these monoclonal antibodies is specific but lacks sensitivity.
INTRODUCTION
Since the initial observations of sequential rotavirus infections (Gust et al., 1977; Fonteyne et al., 1978 ; Rodriguez et al., 1978) , information about antigenic variation in rotavirus strains from a number of species has become available. The first tests for distinguishing such variation amongst human rotaviruses (HRVs) used the non-neutralizing techniques of enzyme immunoassay (EIA) and complement fixation , and, in retrospect, these methods probably differentiated rotavirus subgroups rather than serotypes. It was not until the successful adaptation of HRV to growth in cell culture (Sato et al., 1981; Urasawa et al., 1981) that an appropriate definition of subgroup and serotype was reported and neutralization assays enabling distinction of individual serotypes were developed (Wyatt et al., 1982; Beards & Flewett, 1984) . While gene-coding assignment has previously revealed that the antigenic determinant responsible for subgroup is coded for by gene 6 and that gene 8 or 9, depending on the strain, codes for the serotype-specific determinant Greenberg et al., 1983) more recent information suggests that a further polypeptide, VP3, which is coded by gene 4, may also play a role in serotype specificity (Hoshino et al., 1985b; Offit & Blavat, 1986) . The subgroup determinant is located on a 41000 tool. wt. internal protein (VP6), while the proposed serotype-specific determinants VP3 and VP7 are 88000 and 37000 mol. wt. polypeptides, respectively, located on the outer shell of the virion (Mason et al., 1983) .
Currently, four serotypes of HRV have been identified Beards & Flewett, 1984) and a fifth has recently been reported in association with symptomatic infection in Indonesian children (Matsuno et al., 1985) . Accumulated evidence suggests that the first four serotypes have a world-wide distribution and that each can produce symptomatic infection in neonates, young children and, occasionally, adults. They have also been implicated in asymptomatic neonatal infection (Hoshino et al., 1985a) . Epidemiological information concerning the fifth serotype is lacking. An alternative method by which variation amongst rotavirus strains has been studied involves analysis of individual rotavirus RNA segments following their separation on polyacrylamide gels. This technique, known as 'electropherotyping', does not provide a direct indication of serotype (although, to date, 'short' electrophoretic patterns have been exclusively associated with serotype 2 HRV), but nevertheless provides some insight into the circulation of rotavirus strains within communities. For example, in Melbourne between 1973 and 1979 , the 17 electropherotypes observed showed a sequential pattern of appearance, with a limited number circulating at any one time (Rodger et al., 1981) .
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With the development of candidate rotavirus vaccines Vesikari et al., 1984) it has become important to be able to serotype strains of HRV to determine whether these vaccines provide protection against heterologous as well as homologous serotypes. While serotyping is readily performed on strains isolated in cell culture, most investigators have reported isolation rates of 50~o or less (Wyatt et al., 1982; Birch et al., 1983; Gerna et al., 1984) . The reasons for this are unknown but may be serotype-specific (to date, there have been less isolations made of serotype 2 strains than of the other serotypes), or may relate to the presence of naturally occurring inhibitors in faecal extracts, the lack of sensitivity of some of the cell lines used for isolation, or to the number of incomplete (and, therefore, non-infectious) particles in the specimen.
The inability to identify the serotype associated with all rotavirus infections has encouraged the development of tests for direct serotyping of rotaviruses detected in faecal extracts, thereby eliminating the need for virus isolation. However, the extensive cross-reactions seen when polyclonal antisera are used has made this a difficult task. Thus, the production of monoclonal antibodies that neutralize the virus (and are therefore potentially serotype-specific) has been the aim of several groups (Lambert et al., 1984; Coulson et al., 1985; Shaw et al., 1985; Taniguchi et al., 1985) , one of which has produced a panel of neutralizing monoclonal antibodies having the properties of strain specificity, serotype specificity and common reactivity (Taniguchi et al., 1985) . An important use of these serotype-specific monoclonal antibodies will be as reagents in non-neutralizing tests (such as EIA or latex agglutination) which nevertheless are capable of directly identifying specific HRV serotypes in faecal extracts.
In this report, we describe the production of a panel of monoclonal antibodies with neutralizing activity against HRV serotypes 1, 2, 3 and 4, and the simian rotavirus SA11, and their value in the characterization of 59 rotavirus strains of human, feline and simian origin. Our results show that it is possible to subdivide strains within serotypes 1 and 3 into subclasses and that each serotype 3 subclass has a unique electropherotype. In addition, we present preliminary results to suggest that direct serotyping of rotaviruses in faecal extracts by EIA is possible but lacks the sensitivity of similar tests which utilize monoclonal antibodies specific for the rotavirus subgroup antigen VP6.
METHODS
Viruses. Four human rotavirus strains representing serotypes 1, 2, 3 and 4 and SA11 were used to produce hybridomas secreting monoclonal antibodies. FH4232 (serotype 1) was isolated from a 2-year-old female, FH6139 (serotype 3) was isolated from a neonate, and FH4154 (serotype 4) was isolated from a 1-year-old female. All three patients had symptomatic infection. SA 11 was originally supplied by H. Malherbe and Hu7 (human serotype 2) by Dr J. Albert, Royal Children's Hospital, Melbourne, Australia. The same viruses were used to produce polyclonal sera in guinea-pigs, with the exception of the serotype 4 serum which was raised against an alternative local strain, FH4453. This isolate was obtained from a symptomatic neonate.
Other rotaviruses used were as follows: Wa (human serotype 1, supplied by Dr R. Wyatt), St. Thomas 3 (human serotype 4, supplied by Dr T. Flewett), 47 human strains isolated in Melbourne between 1981 and 1985 from patients with symptomatic rotavirus infection, and four feline strains isolated during a study previously described (Birch et al., 1985) .
All viruses were propagated in African green monkey kidney (CV-1) cells in serum-free minimal essential medium (MEM, Gibco) containing 1.5 btg/ml trypsin (Difco, 1:250) and harvested 1 to 5 days post-infection (Birch et al., 1983) . Faecal specimens and virus supernates were stored at -80 °C.
Virus purification. Virus for immunization was partially purified as previously described (Liu et al., 1984) and then further purified by centrifugation on a CsCI gradient at 200000g for 18 h. The band corresponding to a density of 1.36 g/ml was collected and the presence of outer shell confirmed by PAGE followed by silver staining (Merril et al., 1982) and by negative-staining electron microscopy (EM).
Immunization. (i) Hyperimmune polyclonal sera against representative strains of human serotypes 1, 2, 3 and 4, and SA11 were prepared in guinea-pigs as previously described (Liu et al., 1984) . Antigen preparations contained at least 500 particles per EM grid square. (ii) For the production of hybridomas, 6-week-old male BALB/c mice were immunized intraperitoneally with 0.1 ml of a virus preparation, containing 500 complete particles per EM grid square, in Freund's complete adjuvant, followed 1 to 3 months later with 0.1 ml of the same preparation in incomplete adjuvant via the same route. Seven to 14 days later, 0.4 ml virus was injected intravenously and the mouse sacrificed after a further 3 days.
Hybridoma production. The methods used for the production of monoclonal antibodies were based on those of K6hler & Milstein (1975) and Galfre et al. (1977) . Briefly, l × 108 spleen cells were fused with 2 × 107 Sp2/0 myeloma cells using 50 ~ (w/v) polyethylene glycol 6000 (Merck) and distributed into 96-well Costar plates. Viable hybrids were selected by their outgrowth in HAT medium. Selected hybridomas producing HRV neutralizing antib•diesweresubc••nedtwicebylimitingdi•uti•n.Asciticfluidwas•btainedbyin•cu•ating• × 107hybridoma cells into the peritoneal cavity of pristane-primed mice. The class of immunoglobulin produced by the hybridomas was determined using a mouse monoclonal isotyping kit (C.S.L., Australia).
Neutralization assay. Screening for neutralizing monoclonal antibodies and the determination of neutralizing titres with ascites or polyclonal serum was carried out using a method previously described (Birch et al., 1985) .
Briefly, 50 lul undiluted hybridoma culture fluid or 50 ~tl twofold serial dilutions of ascites or polyclonal serum was reacted with 50 ~tl virus, diluted to contain 1000 TCID50, for 1 h at 37 °C. One-hundred ~tl MEM was added and the infected cells incubated for 16 h at 37 °C. The cells were then fixed in ice-cold methanol and stained with a hyperimmune rabbit anti-rotavirus serum followed by a fluorescein-conjugated antiserum to rabbit IgG (Kallestad, U.S.A.). Neutralization titres were expressed as the reciprocal of the highest dilution of ascitic fluid or serum giving 100~ reduction in fluorescence (Birch et aL, 1985) .
Enzyme immunoassay. The optimal dilution of each serotype-specific ascitic fluid in phosphate-buffered saline (PBS, pH 7.2) was established by preliminary chequerboard titration, and 100 ~tl of each was incubated at 4 °C overnight in 96-well plates (Nunc). After the plates were washed three times with distilled H20, 50 ~tl 0-5 ~ (w/v) bovine serum albumin (BSA) in PBS (PBS-BSA) was added to each well and the plates incubated for 60 min at 37 °C. Following three washes with PBS containing 0.05 ~ Tween 20 (PBS-T) 50 ktl of the test sample [cell culture supernatant or 20~o (w/v) faecal extract] was reacted for 90 min at 37 °C. After six washes with PBS-T, 50 I-d of the optimal dilution of each polyclonal anti-rotavirus serum (in PBS-BSA) was added to separate wells for each sample and the plate incubated at 37 °C for 90 min. After six more washes in PBS-T, horseradish peroxidase-conjugated rabbit immunoglobulins to guinea-pig immunoglobulins (Dako, Copenhagen, Denmark), diluted 1:200 in PBS-BSA, were added and the plate incubated at 37 °C for 60 min. Finally, the plates were washed six times with PBS-T and the substrate (o-phenylenediamine) was added. The reaction was stopped by adding 4 M-H2SO4 after 20 min incubation at room temperature. The absorbance of each well was then measured at 492 nm. Zero was taken as the absorbance of wells incubated with substrate alone. Readings greater than 0.220 were considered positive. This figure was four times the average reading obtained when PBS was used instead ofa rotavirus-positive specimen.
RNA analysis. RNA was extracted from cell culture supernatants using a phenol-SDS procedure as previously described (Birch et al., 1983) . RNA segments were separated by electrophoresis on 10H polyacrylamide slab gels, 1"0 mm thick, for 4 h at a current of 30 mA. Gels were silver-stained before photography (Sammons et al., 1981) .
Preparation ofradiolabelled infected cell lysates. CV-1 monolayers in 35 mm diam. Petri dishes were infected with SAIl or HRV serotype 1 (FH4232) at an m.o.i, between 1 and 10. After 1 h at 37°C the inoculum was removed and the monolayers fed with MEM. At 6 h post-infection the MEM was removed and the monolayer fed with MEM minus methionine or MEM minus glucose, but containing 150 mM excess NaCI and 4rtg/ml actinomycin D. Thirty min later, 30~tCi/ml [3sS]methionine (Amersham) or 25 ~tCi/ml D-[2-3H]mannose (Amersham) was added and incubation continued for 1 h. Monolayers were then washed three times with cold saline and harvested in 50 p.1 of a buffer containing 0.8 M-KC1, 10 mM-Tris-HCl, 1 mr, i-phenylmethylsulphonyl fluoride, 1 ~ Triton X-100, p H 7.8, followed by 200 ~tl of the same buffer without K C1 (Lee et al., 1981 ) . Cell lysates were then spun at 12000 g for 5 min to remove insoluble material, and stored at -80 °C.
Immunoprecipitation. Protein A-Sepharose 4B beads (Pharmacia) were incubated with saturating amounts of rabbit anti-mouse immunoglobulin serum as previously reported (Webster et al., 1983) and washed in RIP buffer (0.05 M-Tris pH 8.0, 1 mM-EDTA, 0.15 M-NaC1). A 50 ~tl aliquot of a 50 ~ suspension of Protein A-Sepharose was mixed with 50 ~1 ascitic fluid and incubated for 1 h at room temperature. After washing three times with RIP buffer containing 0-25~ BSA, 100 ~tl of radiolabelled cell lysate was added and the mixture incubated for 1 h at room temperature. Following three more washes, the beads were suspended in 30 ~1 Laemmli sample buffer, boiled for 3 min, pelleted and the supernatants applied to a 10~ SDS-polyacrylamide slab gel. Radioactive protein bands were detected by autoradiography of cells after enhancement with Amplify (Amersham). :~Numbers in parentheses represent serotypes as determined by polyclonal neutralization.
RESULTS
Production o/neutralizing monoclonal antibodies Following initial screening, 55 stable hybrids secreting neutralizing antibodies to the homologous virus were obtained from five separate fusions. Table 1 summarizes the origin and properties of those hybridomas subsequently subcloned and used in further serotyping experiments.
Serotyping of rotavirus isolates by neutralization
The serotype of each of 59 rotavirus isolates of human, feline and simian origin was initially established by neutralization using the hyperimmune (polyclonal) guinea-pig sera (see representative serotypes in Table 2 ). Attempts were then made to neutralize each isolate using the panel of monoclonal antibodies (see representative results in Table 3 ), cross-neutralization between serotypes, particularly between monoclonal antibody 5Bll (anti-serotype 4) and several serotype 1 and serotype 3 isolates, enabled subdivision of these isolates into a number of subclasses (defined as one or more unique variants within a serotype). For example, monoclonal antibody 5C8 (anti-serotype 1) neutralized 19 of the 26 serotype 1 isolates (see FH4232 in Table 3 ) but did not neutralize the remaining seven (represented by FH6228 in Table 3 ), while monoclonal antibody 5Bll (anti-serotype 4) neutralized all 26 serotype 1 isolates. Neutralization of the serotype 4 isolates by monoclonal antibody 5C8 (anti-serotype 1) did not occur. This one-way cross-reaction between all the serotype 1 isolates and antiserum to serotype 4 isolates was also noted with polyclonal serum (see Table 2 ).
Antigenic analysis of rotaviruses
Within the serotype 3 isolates, which consisted of human, simian and feline rotaviruses, five different subclasses could be distinguished on the basis of neutralization results obtained using the panel of monoclonal antibodies. Subclass one (represented by FH6139 in Table 3 ) was strongly neutralized by monoclonal antibody 3D4 (anti-serotype 3, homologous strain FH6139) and weakly by 2D7 (anti-serotype 3, homologous strain SA 11) and consisted of seven human and two feline isolates (cat 2 and cat 3). Subclass 2 contained only a single isolate (FH6136 in Table 3 ) which was neutralized weakly by 3D4 and 2D7 (the serotype 3 monoclonal antibodies) but strongly by 5B 11 (the serotype 4 monoclonal antibody). Subclass 3 (represented by FH6278 in Table 3 ) contained l0 human isolates which were not neutralized by either 3D4 or 2D7 (antiserotype 3), but were neutralized by 5B11 (anti-serotype 4). Subclass 4 (represented by SA11 in Table 3 ) was only neutralized by 2D7 (anti-SA11). This group also contained a human isolate (FH5972) and a feline isolate (cat 22). Subclass 5 contained a single isolate (cat 97) which was neutralized weakly by 3D4 (anti-serotype 3) but strongly by the other serotype 3 monoclonal antibody (2D7).
Monoclonal antibody 1 C3 (anti-serotype 2) neutralized both the serotype 2 isolates available (see result for Hu7 in Table 3 ), and the seven serotype 4 isolates were neutralized only by 5B11 (anti-serotype 4; see Table 3 for representative neutralization pattern of FH4154).
Serotyping of rotavirus isolates by EIA
The usefulness of the panel of monoclonal antibodies for serotyping 59 cell culture-derived rotaviruses was then assessed using EIA, and Table 4 shows the results obtained for all isolates. Of the 26 isolates identified as serotype 1 by polyclonal neutralization, 19 were confirmed using the EIA. These were the same 19 isolates identified as serotype 1 strains by monoclonal antibody neutralization. Six of these 19 strains also gave a lesser, but still positive, reaction with the serotype 4 monoclonal antibody (5B11) in a manner similar to that given by all 19 strains in the neutralization test. Five of the remaining seven isolates could not be assigned to any serotype, whilst two (FH5501 and FH6349) acted more like serotype 4 strains, apparently on the basis of the cross-reaction with 5B11 (anti-serotype 4).
Both serotype 2 strains (Hu7 and FH1064) were confirmed by monoclonal EIA. Fourteen of the 24 serotype 3 strains were confirmed by EIA but the remaining l0 were not assignable. These 10 non-assignable isolates corresponded exactly to those in subclass 3 as defined by the neutralization results (that is, non-reactive to the serotype 3 monoclonal antibodies 3D4 and 2D7 but reactive to 5B11, the serotype 4 monoclonal antibody). Four of the seven known serotype 4 strains were confirmed by EIA, and the remaining three were not assignable.
RNA analysis of isolates
Electropherotyping revealed three distinct patterns among the serotype 1 isolates (represented by FH4232, FH6228 and FH3575 in Fig. 1 ). There did not appear to be any relationship between electropherotype and the subclasses established by monoclonal neutralization and EIA within the serotype 1 strains. Electropherotyping of all serotype 3 isolates revealed that each of the subclasses 1 to 5 established by neutralization had a unique electropherotype (see Fig. 1 ). Both serotype 2 strains had identical electropherotypes (see Hu7 in Fig. 1) . The six local isolates of serotype 4 rotavirus shared an electropherotype which was R. HEATH, C. BIRCH AND I. GUST ~f These isolates gave a strong reaction with anti-serotype 1 antibody (5C8) but also some reaction with 5B11 (anti-serotype 4 antibody).
:~ r~A, Not assignable. different from that of the reference strain St. Thomas 3. The electropherotype for the local strain FH4154 is shown in Fig. 1 ; the St. Thomas 3 electropherotype is not shown.
Serotyping of rotavirus in faecal extracts by EIA
A limited number of faecal extracts from which isolates were obtained, and which had sufficient volume, were available for direct serotyping experiments using the panel of monoclonal antibodies (see Table 5 ). Of the eight known serotype 1-containing specimens, four were confirmed by the faecal EIA and four were not assignable. Two of the non-assignable specimens (FH4149 and FH5185) contained low levels of rotavirus as determined by E I A using a group-specific monoclonal antibody (results not shown). The remaining two specimens were members of the serotype 1 subclass not neutralized by the serotype 1 monoclonal antibody (5C8) but cross-reacting with the serotype 4 monoclonal antibody (5B 11). When the six faecal extracts known to contain serotype 3 strains were tested, two (both corresponding to subclass 1) were confirmed. Three of the four non-assignable serotype 3 strains were members of subclass 3 and one (FH6511) corresponded to subclass 1. There were no faecal extracts containing serotype 2 viruses available; of the two serotype 4-containing specimens tested, neither was assignable. R. HEATH, C. BIRCH AND I. GUST 
Reaction of 16 rotavirus-positive faecal extracts by EIA

Temporal distribution of rotavirus serotypes and groups
All of the assignable serotype 1 isolates circulated between October 1981 and August 1984. Only one of seven non-assignable strains was detected during this period (in June 1984); the remaining six occurred between June and August 1985.
Human serotype 3 strains of subclasses 1, 2, 3 and 4 circulated between November 1983 and April 1985, and the feline strains also circulated during this period. From May to July 1985 all the serotype 3 isolates (nine in total) were subclass 3 and from August to September all were subclass 1 (a further five isolates).
All six serotype 4 isolates occurred in a 6-month period between July 1982 and January 1983. The only serotype 2 strain (FH1064) was isolated from a specimen collected in June 1978.
Radioimmunoprecipitation
When SAIl-and FH4232-infected cells were labelled with [3SS]methionine, viral polypeptides at mol. wt. similar to those reported by Ericson et al. (1982) were present (Fig. 2a, i respectively). In an attempt to improve the resolution of the 34000 to 38000 mol. wt. glycoprotein (VP7) of SAIl and FH4232, we also labelled the viral glycoprotein with [3H]mannose, since VP7 of SA 11 is known to have a high mannose content (Ericson et al., 1982) .
Following [3H]mannose labelling of SAIl-and FH4232-infected cells, viral polypeptides corresponding to VP7 and a number of smaller mol. wt. polypeptides could be identified (Fig.  2d, I respectively) .
In immunoprecipitation studies with SAIl, the homologous neutralizing monoclonal antibody 2D7 immunoprecipitated VP7 when it was labelled with [35S]methionine (see arrow, Fig. 2c ). 5G6, a non-neutralizing monoclonal antibody which reacts with all rotavirus serotypes by EIA and immunofiuorescence (results not shown) and also immunoprecipitates VP6, was included as a control (Fig. 2b) . 2D7 also immunoprecipitated VP7 of SA11 labelled with [3H]mannose (see arrow, Fig. 2f ). 5G6 (Fig. 2e) and mouse ascites produced with SP2/0 myeloma cells (Fig. 2g ) did not react with VP7.
In immunoprecipitation studies with FH4232, the homologous neutralizing monoclonal antibody 5C8 did not immunoprecipitate any of the virus-specific polypeptides labelled with [3SS]methionine or [3H]mannose (Fig. 2k, n respectively) . Further tests with the neutralizing monoclonal antibodies IC3 and 3D4 also failed to immunoprecipitate any of the HRV polypeptides of Hu7 and FH6139 respectively (results not shown). Ericson et al. (1982) . Molecular weights of marker proteins are given on the right.
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DISCUSSION
The results presented in this study strongly suggest that antigenic variation occurs within rotavirus serotypes. This is particularly true of serotype 3 viruses but is also a property of serotype 1 strains. We have no direct evidence of antigenic variation among serotype 2 and 4 strains but we were only able to study a small number of isolates of these serotypes. When the temporal distribution of the isolates was analysed it was found that all of the 19 assignable serotype 1 strains were isolated during a 3-year period between 1981 and 1984, and six of the seven non-assignable serotype 1 strains then occurred during a 2-month period during 1985. A similar pattern of circulation occurred among the serotype 3 isolates, with the majority of subclass 3 strains (nine of ten) circulating in the period May to July 1985, and five of the seven subclass I strains circulating in August and September of the same year. Hence, there appears to be independent circulation of subclasses within serotypes in a manner similar to that previously described for the circulation of electropherotypes (Rodger et al., 1981) . We believe that the demonstration of a number of rotavirus subclasses within serotypes is similar to the antigenic variation occurring amongst polioviruses as described by Crainic et al. (1983) who used a panel of monoclonal antibodies to define several distinct neutralization epitopes for each of the three recognized serotypes.
Variation among human serotype 3 isolates has been previously reported by Coulson et al. (1985) who demonstrated antigenic differences between two neonatal strains isolated 3 months apart. Both strains had identical electropherotypes but showed different neutralization and EIA patterns when tested with a serotype 3 monoclonal antibody. Although we confirmed this observation of antigenic variation, our results showed that serotype 3 isolates sharing identical electropherotypes reacted similarly in monoclonal antibody neutralization and EIA tests.
Our results also show that variation occurs within non-human strains of the same serotype. Four feline isolates previously shown to be serotype 3 (Birch et al., 1985) have been demonstrated by the present study to belong to three separate subclasses. Of added interest is the finding that two of these strains (cat 2 and cat 3) are indistinguishable from seven human strains also isolated in this laboratory, thus leaving open the possibility of naturally occurring feline-toman transmission.
The first report of a neutralizing monoclonal antibody against HRV was made by Lambert et al. (1984) against a Belgian isolate. However, the specific polypeptide to which this monoclonal antibody bound could not be demonstrated. Other groups reporting the production of neutralizing monoclonal antibodies (Coulson et al., 1985; Taniguchi et al., 1985) have also experienced difficulties in characterizing them, although Taniguchi et al. (1985) , who produced monoclonal antibodies against HRV serotypes 1, 2 and 3, demonstrated that several of these were directed against VP3, the viral haemagglutinin which is associated with the outer shell of the virion. However, there have been no reports which directly show the existence of a neutralizing monoclonal antibody against VP7, the major outer-shell polypeptide associated with serotype. We have tried Western blots (results not shown) and variations of immunoprecipitation, including the use of Protein A-Sepharose with and without rabbit antimouse immunoglobulin, elimination of detergents from lysates and buffers, use of different incubation conditions, and use of concentrated and purified ascitic and culture fluids, but without success (results not shown). Taniguchi et al. (1985) suggested that conformational changes in the VP7 glycoprotein within the cell lysate might explain the failure of these monoclonal antibodies to immunoprecipitate the relevant protein. Why this should be a property of the human strains but not those from other species is unclear.
Of relevance to the findings of Taniguchi et al. (1985) that some neutralizing monoclonal antibodies react against VP3 by immunoprecipitation, Offit & Blavat (1986) have recently shown that rotavirus gene segments 4 and 9 (coding for VP3 and VP7, respectively, ofSAl 1 and the bovine rotavirus NCDV) both play a role in virus neutralization and, in unpublished data, showed that VP3-and VP7-specific monoclonal antibodies, prepared against a rhesus monkey rotavirus, protected suckling mice challenged with a virulent rotavirus strain. In addition, Hoshino et al. (1985 b) have reported a Venezuelan rotavirus isolate (M37) which appears to be a naturally occurring intertypic virus, with its VP3 being related to a serotype 4 rotavirus (St. Thomas 3) and its VP7 being similar or identical to that of the Wa (serotype 1) strain. It was shown that the relationship between M37 and the St. Thomas strain was one-way, apparently on the basis of shared antigenic determinants on VP3. Because our results show a similar one-way cross between our serotype 1 and 4 isolates, it is possible that our serotype 4 isolates could be M37-1ike viruses. We have previously considered these isolates to be similar or identical to the St. Thomas 3 strain based on our observations that antiserum to one of them (FH4453) neutralizes the St. Thomas 3 strain. However, this does not eliminate the possibility that they represent naturally occurring intertypic strains as described by Hoshino et al. (1985b) and we intend to investigate them further.
In preliminary experiments during the development of our indirect monoclonal EIA, we used the serotype-specific polyclonal antisera as capture antibodies and the monoclones as the second antibody. However, the reactions observed were extremely weak. We therefore reversed the procedure and used the monoclonal antibodies as capture antibodies, where they presumably bind only to complete virus particles, and the polyclonal sera as the second antibody, where they have the potential to react with both complete and incomplete particles. The final EIA developed for serotyping of all culture supernates was specific. It detected all the serotype 1, 2 and 3 strains as determined by monoclonal neutralization and did not give any non-specific results with the non-assignable strains. However, it appeared to be less sensitive in detecting serotype 4 isolates. A consistent observation in this laboratory has been the ease with which serotype 4 strains lose their outer shell, and this may explain the reduced sensitivity of the test for viruses of this serotype.
Our attempts to serotype directly the rotaviruses in faecal extracts revealed that, although specific, the EIA test lacked sensitivity compared with tests detecting the common inner protein VP6. This is a not unexpected result as incomplete or partly damaged particles are usually in excess of intact particles in faecal extracts. The relative insensitivity of such assays appears to be a limiting factor in the use of monoclonal antibodies in tests requiring serotype identification, and optimal results will probably be achieved using a combination of direct monoclonal EIA and virus isolation.
We are currently evaluating the usefulness of our monoclonal antibody panel for serotypic identification of more than 1000 rotavirus-positive extracts stored since 1975. In addition, we are making monoclonal antibodies against non-assignable serotype 1 and 3 isolates in the hope that their inclusion in the monoclonal antibody panel will result in improvements in the serotype identification rate currently achieved. Further epidemiological studies planned might also shed some light on whether or not the antigenic variation we have observed will influence the efficacy of rotavirus vaccines.
